[{"orgOrder":0,"company":"CellTrans","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Donislecel","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"CellTrans","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"CellTrans \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CellTrans \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by CellTrans

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Lantidra (donislecel-jujn suspension for hepatic portal vein infusion) is an allogeneic pancreatic islet cellular therapy y indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c.

                          Product Name : Lantidra

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 29, 2023

                          Lead Product(s) : Donislecel

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank